Terug
58
37
Dagbereik
€ 267,59
€ 273,38
52-Weeksbereik
€ 234,60
€ 606,36
Volume
5.890.739
50D / 200D Gem.
€ 298,51
/
€ 314,23
Vorige Slotkoers
€ 269,54
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 20,5 | 0,4 |
| P/B | 2,6 | 2,9 |
| ROE % | 12,9 | 3,9 |
| Net Margin % | 2,7 | 3,8 |
| Rev Growth 5Y % | 11,7 | 10,0 |
| D/E | 0,8 | 0,2 |
Koersdoel Analisten
Hold
€ 385,38
+41.5%
Low: € 327,00
High: € 444,00
Forward K/W
15,1
Forward WPA
€ 17,85
WPA Groei (sch.)
+0,0%
Omzet Sch.
440 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 32,46
€ 31,77 – € 34,06
|
540 B | 4 |
| FY2029 |
€ 28,68
€ 28,07 – € 30,10
|
510 B | 4 |
| FY2028 |
€ 23,78
€ 22,33 – € 26,27
|
480 B | 10 |
Insider Trading Activity
18 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 |
Baker Charles D.
Director
|
grant | 14 | — | — |
| Feb 20, 2026 |
ROOS THOMAS E
Chief Accounting Officer
|
other | 326 | € 290,00 | € 94.540 |
| Jan 2, 2026 |
Gottlieb Scott
Director
|
grant | 125 | — | — |
| Jan 2, 2026 |
Baker Charles D.
Director
|
grant | 279 | — | — |
| Dec 16, 2025 |
MCNABB FREDERICK WILLIAM III
Director
|
grant | 53 | — | — |
| Oct 1, 2025 |
FLYNN TIMOTHY PATRICK
Director
|
grant | 272 | — | — |
| Sep 23, 2025 |
FLYNN TIMOTHY PATRICK
Director
|
grant | 61 | — | — |
| Sep 23, 2025 |
MCNABB FREDERICK WILLIAM III
Director
|
grant | 49 | — | — |
| Sep 11, 2025 |
Baker Charles D.
Director
|
sell | 27 | € 356,05 | € 9.613 |
| Jul 1, 2025 |
MONTGOMERY RICE VALERIE MD
Director
|
grant | 288 | — | — |
| Jul 1, 2025 |
Gil Kristen
Director
|
grant | 173 | — | — |
| Jun 24, 2025 |
Noseworthy John H
Director
|
grant | 42 | — | — |
| Jun 24, 2025 |
Noel Timothy John
Chief Executive Officer, UHC
|
grant | 48 | — | — |
| Jun 6, 2025 |
McSweeney Erin
EVP & Chief People Officer
|
other | 130 | € 303,22 | € 39.419 |
| Jun 3, 2025 |
Zaetta Christopher R
EVP & Chief Legal Officer
|
other | 115 | € 301,22 | € 34.640 |
| May 14, 2025 |
FLYNN TIMOTHY PATRICK
Director
|
buy | 1.533 | € 320,80 | € 491.786 |
| Apr 1, 2025 |
Gil Kristen
Director
|
grant | 108 | — | — |
| Apr 1, 2025 |
HOOPER MICHELE J
Director
|
grant | 108 | — | — |
Belangrijkste Punten
Revenue grew 11,69% annually over 5 years — strong growth
Earnings declined -16,31% over the past year
ROE of 12,91% — decent returns on equity
Generating 16,08B in free cash flow
Cash machine — converts 133,34% of earnings into free cash flow
Capital efficient — spends only 0,81% of revenue on capex
Groei
Revenue Growth (5Y)
11,69%
Revenue (1Y)11,81%
Earnings (1Y)-16,31%
FCF Growth (3Y)-20,88%
Kwaliteit
Return on Equity
12,91%
ROIC8,25%
Net Margin2,69%
Op. Margin4,24%
Veiligheid
Debt / Equity
0,83
Current Ratio0,79
Interest Coverage4,74
Waardering
P/E Ratio
20,50
P/B Ratio2,63
EV/EBITDA15,88
Dividend Yield0,03%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11,81% | Revenue Growth (3Y) | 9,74% |
| Earnings Growth (1Y) | -16,31% | Earnings Growth (3Y) | -26,61% |
| Revenue Growth (5Y) | 11,69% | Earnings Growth (5Y) | -8,61% |
| Profitability | |||
| Revenue (TTM) | 447,57B | Net Income (TTM) | 12,06B |
| ROE | 12,91% | ROA | 3,89% |
| Gross Margin | 18,53% | Operating Margin | 4,24% |
| Net Margin | 2,69% | Free Cash Flow (TTM) | 16,08B |
| ROIC | 8,25% | FCF Growth (3Y) | -20,88% |
| Safety | |||
| Debt / Equity | 0,83 | Current Ratio | 0,79 |
| Interest Coverage | 4,74 | Dividend Yield | 0,03% |
| Valuation | |||
| P/E Ratio | 20,50 | P/B Ratio | 2,63 |
| P/S Ratio | 0,55 | PEG Ratio | -1,62 |
| EV/EBITDA | 15,88 | Dividend Yield | 0,03% |
| Market Cap | 247,14B | Enterprise Value | 301,17B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 447,57B | 400,28B | 371,62B | 324,16B | 287,60B |
| Net Income | 12,06B | 14,41B | 22,38B | 20,12B | 17,29B |
| EPS (Diluted) | 13,23 | 15,51 | 23,86 | 21,18 | 18,08 |
| Gross Profit | 82,92B | 89,40B | 90,96B | 79,62B | 69,65B |
| Operating Income | 18,96B | 32,29B | 32,36B | 28,44B | 23,97B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 309,58B | 298,28B | 273,72B | 245,71B | 212,21B |
| Total Liabilities | 207,88B | 195,69B | 174,80B | 159,36B | 135,73B |
| Shareholders' Equity | 94,11B | 92,66B | 88,76B | 77,77B | 71,76B |
| Total Debt | 78,39B | 76,90B | 67,44B | 57,62B | 46,00B |
| Cash & Equivalents | 24,37B | 25,31B | 25,43B | 23,37B | 21,38B |
| Current Assets | 90,58B | 85,78B | 78,44B | 69,07B | 61,76B |
| Current Liabilities | 114,90B | 103,77B | 99,05B | 89,24B | 78,29B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#250 of 1052
#284 of 618
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026